BioCryst Pharmaceuticals
BCRX
BCRX
299 hedge funds and large institutions have $2.36B invested in BioCryst Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 114 increasing their positions, 76 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
10% more funds holding
Funds holding: 273 → 299 (+26)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.18% less ownership
Funds ownership: 100.86% → 98.68% (-2.2%)
Holders
299
Holding in Top 10
3
Calls
$14.2M
Puts
$6.09M
Top Buyers
| 1 | +$85.6M | |
| 2 | +$37.1M | |
| 3 | +$33.2M | |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$32.1M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$31.1M |
Top Sellers
| 1 | -$28.6M | |
| 2 | -$22M | |
| 3 | -$16.9M | |
| 4 |
Squarepoint
New York
|
-$12.6M |
| 5 |
Renaissance Technologies
New York
|
-$10.5M |
